Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALC 
Alcon AG (ALC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ALC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
27 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $96.14
1 Year Target Price $96.14
| 15 | Strong Buy |
| 6 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.18% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 37.38B USD | Price to earnings Ratio 34.91 | 1Y Target Price 96.14 |
Price to earnings Ratio 34.91 | 1Y Target Price 96.14 | ||
Volume (30-day avg) 27 | Beta 0.69 | 52 Weeks Range 71.55 - 98.85 | Updated Date 10/17/2025 |
52 Weeks Range 71.55 - 98.85 | Updated Date 10/17/2025 | ||
Dividends yield (FY) 0.44% | Basic EPS (TTM) 2.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.7% | Operating Margin (TTM) 11.17% |
Management Effectiveness
Return on Assets (TTM) 2.64% | Return on Equity (TTM) 4.98% |
Valuation
Trailing PE 34.91 | Forward PE 20.96 | Enterprise Value 41024467443 | Price to Sales(TTM) 3.73 |
Enterprise Value 41024467443 | Price to Sales(TTM) 3.73 | ||
Enterprise Value to Revenue 4.09 | Enterprise Value to EBITDA 14.95 | Shares Outstanding 494400000 | Shares Floating 493346928 |
Shares Outstanding 494400000 | Shares Floating 493346928 | ||
Percent Insiders 0.13 | Percent Institutions 69.75 |
Upturn AI SWOT
Alcon AG
Company Overview
History and Background
Alcon AG traces its roots back to a Fort Worth, Texas pharmacy in 1945. Originally focusing on pharmaceuticals, it expanded into ophthalmic products. Nestle acquired Alcon in 1977. Novartis then acquired Nestle's stake in Alcon, completing the acquisition in 2011. Alcon spun off from Novartis in 2019 and is now an independent publicly traded company based in Geneva, Switzerland.
Core Business Areas
- Surgical: Offers products for cataract surgery, vitreoretinal surgery, refractive surgery, and advanced technology intraocular lenses (IOLs).
- Vision Care: Includes contact lenses (daily disposables, monthly, etc.) and lens care products for cleaning, disinfecting, and storing contact lenses.
Leadership and Structure
Alcon AG is led by CEO David J. Endicott. The company has a board of directors that oversees the management team. Alcon operates globally with regional headquarters and sales offices.
Top Products and Market Share
Key Offerings
- Product Name 1: Dailies Total1 Contact Lenses: Premium daily disposable contact lenses. Competes with Johnson & Johnson's Acuvue Oasys 1-Day, Bausch + Lomb's Infuse and CooperVision's MyDay. Estimates suggest Alcon holds a significant market share in the daily disposable contact lens market. Itu2019s difficult to parse the precise market share for just this product. However, contact lens and care products made up $3.6 billion of the 2023 revenue. Competitors include: Johnson & Johnson (JNJ), Bausch Health Companies (BHC), CooperCompanies (COO).
- Product Name 2: Clareon IOL: A hydrophobic acrylic intraocular lens used in cataract surgery. Competes with Johnson & Johnson's Tecnis IOLs, Bausch + Lomb's enVista IOLs, and Carl Zeiss Meditec's IOLs. Again, hard to parse precise market share, but surgical products contributed $5.6 billion to total 2023 revenue. Competitors include: Johnson & Johnson (JNJ), Bausch Health Companies (BHC), Carl Zeiss Meditec (AFX.DE).
Market Dynamics
Industry Overview
The ophthalmic market is driven by an aging population, increasing prevalence of eye diseases (cataracts, glaucoma, etc.), and growing demand for vision correction solutions. Technological advancements are also a key factor.
Positioning
Alcon AG is a leading player in the ophthalmic market with a broad portfolio of surgical and vision care products. Its competitive advantages include a strong brand reputation, established distribution channels, and a focus on innovation.
Total Addressable Market (TAM)
The global ophthalmic market is estimated to reach $60+ Billion by 2028. Alcon AG is well-positioned to capture a significant share of this TAM through its diversified product portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Leading market position in ophthalmic products
- Strong brand recognition
- Diversified product portfolio
- Global distribution network
- Focus on innovation
Weaknesses
- Exposure to competition from established players
- Dependence on innovation for growth
- Potential for product recalls
- Regulatory hurdles
Opportunities
- Growth in emerging markets
- Development of new technologies (e.g., digital health)
- Expansion into adjacent markets
- Strategic acquisitions
Threats
- Increased competition
- Price erosion
- Economic downturns
- Changes in regulations
Competitors and Market Share
Key Competitors
- JNJ
- BHC
- COO
Competitive Landscape
Alcon AG has a strong competitive position due to its broad product portfolio and global presence. However, it faces competition from other established players, as well as smaller, more specialized companies.
Major Acquisitions
Ivantis
- Year: 2022
- Acquisition Price (USD millions): 475
- Strategic Rationale: Expanded Alcon's glaucoma portfolio with Ivantis' Hydrus Microstent.
Growth Trajectory and Initiatives
Historical Growth: Alcon has experienced steady growth in revenue and profitability since its spin-off. Growth has been driven by new product launches and expansion in key markets.
Future Projections: Analysts project continued growth for Alcon AG, driven by increasing demand for ophthalmic products and the company's strong product pipeline.
Recent Initiatives: Recent strategic initiatives include investments in R&D, expansion into new markets, and strategic acquisitions to strengthen its product portfolio.
Summary
Alcon AG is a strong player in the ophthalmic market with a diversified product portfolio and global presence. The company has experienced steady growth since its spin-off and is well-positioned for future growth. However, Alcon faces competition from other established players and needs to continue to invest in innovation to maintain its competitive advantage. Investors should be aware of risks associated with regulatory changes and economic downturns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Alcon AG Financial Reports
- Market Research Reports (e.g., from Grand View Research, Market Research Future)
- Analyst Reports
- Company Website
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change over time. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alcon AG
Exchange NYSE | Headquaters - | ||
IPO Launch date 2019-04-09 | CEO & Director Mr. David J. Endicott | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 25000 | Website https://www.alcon.com |
Full time employees 25000 | Website https://www.alcon.com | ||
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.